Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results

(European Society of Cardiology) Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.The research was presented today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.